Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma
Tumuluru, S.; Godfrey, J. K.; Cooper, A.; Yu, J.; Chen, X.; MacNabb, B. W.; Venkataraman, G.; Zha, Y.; Pelzer, B.; Song, J.; Duns, G.; Sworder, B. J.; Bolen, C.; Penuel, E.; Postovalova, E.; Kotlov, N.; Bagaev, A.; Fowler, N.; Smith, S. M.; Alizadeh, A. A.; Steidl, C.; Kline, J.
Show abstract
Most diffuse large B-cell lymphoma (DLBCL) patients treated with bispecific antibodies (BsAb) or chimeric antigen receptor (CAR) T cells fail to achieve durable treatment responses, underscoring the need for a deeper understanding of mechanisms that regulate the immune environment and response to treatment. Here, an integrative, multi-omic approach was employed to characterize DLBCL immune environments, which effectively segregated DLBCLs into four quadrants - termed DLBCL-immune quadrants (IQ) - defined by cell-of-origin and immune-related gene set expression scores. Recurrent genomic alterations were enriched in each IQ, suggesting that lymphoma cell-intrinsic alterations contribute to orchestrating unique DLBCL immune environments. In relapsed/refractory DLBCL patients, DLBCL-IQ assignment correlated significantly with clinical benefit with the CD20 x CD3 BsAb, mosunetuzumab, but not with CD19-directed CAR T cells. DLBCL-IQ provides a new framework to conceptualize the DLBCL immune landscape and uncovers the differential impact of the endogenous immune environment on outcomes to BsAb and CAR T cell treatment.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed/Refractory Diffuse Large B Cell Lymphoma 95%
- Microenvironmental correlates of immune checkpoint inhibitor response in human melanoma brain metastases revealed by T cell receptor and single-cell RNA sequencing 94%
- Tertiary lymphoid structures are associated with enhanced macrophage activation, immune checkpoint expression and predict outcome in cervical cancer. 93%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia 94%
- KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response 94%
- Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies 94%
Similar papers in this journal
- Single-cell spatial analysis of tumor immune architecture in diffuse large B cell lymphoma 97%
- Single-cell profiling identifies clinically relevant interactions between tumor associated macrophages and blood endothelial cells in diffuse large B cell lymphoma 95%
- Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged organ-tropism 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.